Coffin CS, Vienneau J, Cooper CL, Doucette KE, Elkashab M, Ko HH, Ramji A, Tam E, Fung SK, Congly SE, Crotty P, Chen A, Crawley AM, Lamboo LL, Lee ER, Osiowy C. Ultrasensitive detection of HBsAg and HBV genome analysis in a prospective cohort with chronic hepatitis B after HBV surface antigen loss. Hepatology Communications, 2025; 9(12):e0854, DOI: 10.1097/HC9.0000000000000854 (Article link)
Osiowy C, Alvarez F, Coffin C, Cooper CL, Fung SK, Ko HH, Poulin S, van Gennip J. The management of chronic hepatitis B: 2025 guidelines update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada. Canadian Liver Journal, 2025; 8(2). (Article link)
Sachar Y, Li X, Mukhtar N, Khalili M, Coffin C, Brahmania M. External validation of random survival forest machine learning model for risk stratifying Chronic Hepatitis B Patients regarding HCC. Abstract submitted to International Liver Cancer Association (ILCA) Single Topic Conference, 2024.
Hercun J, Kochaksaraei GS, D'souza S et al., Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: 'Progress toward hepatitis B elimination in Canada'. Canadian Liver Journal, 2024; 7(3): 385-411. (Article link)
Sachar Y, Congly SE, Burak KW, et al., Epidemiology, treatment patterns and survival in Canadian patients with Chronic Hepatitis B-related hepatocellular carcinoma. Journal of Viral Hepatitis, 2024; 0:1-7. (Article link)
Patel NH, Lucko A, Vachon A, et al., Assessment of HBV variants and novel viral immune biomarkers in chronic hepatitis B patients with metabolic dysfunction associated liver disease. Journal of Viral Hepatitis, 2024; 00:1-10. (Article link)
Wang S, Coffin CS, Tang A, et al., What will it take to eliminate hepatitis B as a public health threat in the United States and Canada? Clinical Liver Disease 2024, 23(1): e0182. DOI: 10.1097/CLD.0000000000000182. (Article link)
Keeshan A., da Silva CF, Vachon A, et al., Hepatitis B Virus Genotype Influence on Virological and Enzymatic Measures over Time—A Retrospective Longitudinal Cohort Study. J. Clin. Med. 2023, 12, 6807. (Article link)
Zoughlami A, Serero J, Congly S, et al., Diagnosis of esophageal varices by liver stiffness and serum biomarkers in virus-related compensated advanced chronic liver disease. Canadian Liver Journal. September 2023. DOI: 10.3138/canlivj-2022-0047 (Article link)
Keeshan A, Coffin CS, Vachon A, et al., Ribavirin does not enhance hepatitis B virus nucleotide antiviral activity: a pilot study. Clin. Invest. Med. Dec. 2022; 45(4): E11-15. doi: 10.25011/cim.v45i4.39274. (Article link)
Coffin CS, Haylock-Jacobs S, Doucette K, et al., Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA). Viruses Nov. 2022; 14(12): 2668 (Article link).
Sarowar A, Coffin C, Fung S, et al., Effect of antiretroviral switch from TDF to TAF, lipid profiles and renal function in HIV/HBV co-infected individuals in a nationwide Canadian study. JAIDS 2022. [DOI: 10.1097/QAI.0000000000003079]. (Article link)
Ramji A, Doucette K, Cooper C, et al., Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue. World J Gastroenterol 2022; 28(31): 4390-4398 [DOI: 10.3748/wjg.v28.i31.4390] (Article link)
Osiowy C, Swidinsky K, Haylock-Jacobs S, et al., Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada, JHEP Reports, 2022. (Article link)
This HDV study was featured in the "Science of Health" blog by Government of Canada: Hepatitis D research highlights need for increased screening - Science.gc.ca
Ko HH, Patel NH, Haylock-Jacobs S, et al., Severe hepatic steatosis is associated with low level viremia and advanced fibrosis in chronic hepatitis B patients in North America, Gastro Hep Advances, 2021. (Article link)
Farag M, Fung S, Tam E, et al., Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study, J Viral Hep, 2021; 28(6): 942-950. [FOI: 10.1111/JVH.13500]. (Article link)
Joshi S, Davis R, Ma M, et al., Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD), NPJ Vaccines, vol. 9, no. 9, 2021. (Article link)
Cooper C, Dreidger M, Wong D, et al., Distinct Hepatitis B and HIV co-infected populations in Canada, J Viral Hep, vol. 28 , no. 3, p 517-527. (Article link)
Coffin CS, Ramji A, Cooper CL, et al., Epidemiologic and Clinical Features of Chronic Hepatitis B Virus Infection in 8 Canadian provinces: a Descriptive Study by The Canadian HBV Network, CMAJ Open, vol. 7, no. 4, p E610-E617. (Article link) (Commentary in CMAJ Print Edition, December 2019, page 28)
Yau, A, Galorport C, Coffin CS, and Ko HH, Hepatocellular Carcinoma Screening Practices in Chronic Hepatitis B among Canadian Gastroenterologists and Hepatologists: An Online Survey, Can Liv J, vol. 2, no. 4, p199-209. (Article link)
Coffin CS, Fung SK, Alvarez F, Cooper CL, et al., Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada, Can Liv J, vol 1, no. 4, p 156-217. (Article link)
CLINICAL RESEARCH
Currently active studies:
Burden of Hepatitis B Virus (HBV) and Hepatitis Delta Virus (HDV) Coinfection in Canada: The Canadian HBV Network
A Study to Determine Benefits of Hepatitis B Surface Antigen (HBsAg) Loss in a Multiethnic Cohort of Untreated and Treated Patients with Chronic Hepatitis B Infection
Identification and Characterization of Barriers to Treatment in Hepatitis B Patients Followed by the Canadian Hepatitis B Network
Previous (completed) studies:
Real-World Effectiveness and Renal Safety of Tenofovir Alafenamide Among Chronic Hepatitis B Patients in Canada
A Prospective Study of HBV Immunity and HBV Vaccination in Patients with NAFLD in Canada (clinicaltrials.gov)
Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity (clinicaltrials.gov)
Determination of Clinical and Molecular Properties of Hepatitis B Virus (HBV) in the Context of Concomitant Chronic Hepatitis B and Non-Alcoholic Fatty Liver Disease (NAFLD)
RESEARCH INTERESTS
Our primary interest is in advancing excellence in Hepatitis B patient care, research and education.
Current research is focused in three main areas: